GTBP GT Biopharma, Inc.
Legal ·
GT Biopharma is the only defendant named in New York suits by Z-One, Silberfein, DiPietro and the Werthman Trust. Z-One's claims were dismissed and appealed. The other three are in settlement talks.
On March 1, 2026 the audit committee concluded the quarterly reports contained an error: Greenshoe Rights from a May 2025 private placement required liability classification. GT Biopharma (Nasdaq: GTBP) will file Forms 10-Q/A.
Nasdaq told GT Biopharma on November 20, 2025 that its stock had closed below $1 for 30 consecutive business days. The company has until May 19, 2026 to regain compliance, and its last annual report carried a going-concern warning alongside a $13.2 million net loss.
A new purchaser joined the Series L 10% Convertible Preferred deal, which now carries an aggregate purchase price of $5,950,000.00. Buyers also hold greenshoe rights for up to $21,616,514 more.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $3.5 million | $5.8 million |
| Net income (loss) | -$28.4 million | -$13.2 million |
| Cash from operations | -$12.9 million | -$12.9 million |
| Cash and equivalents | $6.8 million | $4.0 million |
Our latest story on this, dated Nov 26, 2025: "GT Biopharma gets Nasdaq minimum bid price notice, has until May 19, 2026 to regain compliance". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 2, 2026: "GT Biopharma issues non-reliance notice, will restate June and September 2025 quarterly financials". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "GT Biopharma sued by four convertible note holders over undelivered conversion shares". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "GT Biopharma sued by four convertible note holders over undelivered conversion shares". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "GT Biopharma sued by four convertible note holders over undelivered conversion shares". The story links the filing or release it is based on. Read the story.
GT Biopharma, Inc. trades under the ticker GTBP on NASDAQ.
GT Biopharma, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for GT Biopharma, Inc. is 109657. Its filings are on SEC EDGAR.
45,109,497 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.
Our directory records GT Biopharma, Inc. under United States.
Our directory classifies GT Biopharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for GT Biopharma, Inc. is US36254L4077.
aibio.space lists GT Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
GT Biopharma, Inc. reported a net loss of $28.4 million for the fiscal year ended Dec 31, 2025, and used $12.9 million of cash in operations, per its annual report to the SEC.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio